Quantitative- And Phospho-Proteomic Analysis of the Yeast Response to the Tyrosine Kinase Inhibitor Imatinib to Pharmacoproteomics-Guided Drug Line Extension

OMICS A Journal of Integrative Biology - United States
doi 10.1089/omi.2012.0012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats

PLoS ONE
Multidisciplinary
2015English

Real-Time Nanoscale Proteomic Analysis of the Novel Multi-Kinase Pathway Inhibitor Rigosertib to Measure the Response to Treatment of Cancer

Expert Opinion on Investigational Drugs
MedicinePharmacology
2013English

Analysis of Onset Mechanism for Tyrosine Kinase Inhibitor Imatinib Induced-Left Ventricular Diastolic Dysfunction

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Response to MEK Inhibition With Trametinib and Tyrosine Kinase Inhibition With Imatinib in Multifocal Histiocytic Sarcoma

Haematologica
Hematology
2017English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy
OncologyPharmacology
2016English

A Guide to the Quantitative Proteomic Profiles of the Cancer Cell Line Encyclopedia

2020English

Yeast Dun1 Kinase Regulates Ribonucleotide Reductase Inhibitor Sml1 in Response to Iron Deficiency

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2014English

A Quantitative Proteomic Analysis of Cofilin Phosphorylation in Myeloid Cells and Its Modulation Using the LIM Kinase Inhibitor Pyr1

PLoS ONE
Multidisciplinary
2018English

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy